Despite impressive advances over the years, [1] there are still important transformations that lack catalytic asymmetric variants. While Lewis acid catalyzed additions of allylsilanes to carbonyl compounds [2] and acetals [3] have been well studied using catalytic, [4] as well as auxiliary-based methods to control absolute configuration, [5] to the best of our knowledge, there are no effective methods for catalyzing the asymmetric 1,4-addition of allyltrimethylsilane to unsaturated carbonyl compounds. [6] In that regard, we report herein a catalytic enantioselective conjugate addition of allyltrimethylsilane to various activated cyclic enones with selectivities surpassing 98 % ee. The 1,4-addition of the air-and moisture-stable nucleophile to unsaturated carbonyl compounds proceeds to > 95 % conversion in the presence of Cu(OTf) 2 (10 mol %) with the commercially available di(tert-butyl)bis(oxazoline) (box) ligand (2). [7] We show how these products can be functionalized to a variety of useful enantiomerically enriched systems.Our initial studies into the development of a chiral Lewis acid catalyst indicated that simple cyclic and acyclic a,bunsaturated carbonyls (ketones and esters) did not react with a variety of metal-ligand combinations.[8] We therefore sought to activate the substrate by installation of a second electron-withdrawing/chelating group at the a-position of the enone (i.e., 1). In the presence of Cu(OTf) 2 (7 mol %) and bis(oxazoline) ligand 2 (8 mol %) in Cl(CH 2 ) 2 Cl, we obtained the desired 1,4-allyl-addition product 3 in > 95 % conversion (after 30 min at 0 8C) and 72 % ee as a mixture of keto-enol tautomers (Scheme 1). Alternative solvents (CH 2 Cl 2 , Et 2 O, toluene, EtOAc, etc.) and metal salts, including other copper salts, resulted in lower selectivities.[9] Other chiral ligands (e.g., peptide-based, [10] salen, [11] Trost ligand [12] ) led to high conversion (> 95 %), but with low selectivity (< 5 % ee).To identify a more effective catalyst, we prepared and screened approximately 40 mono-and bis(oxazoline) ligands.